The serum MPO levels of breast cancer patients treated with doxorubicin and paclitaxel followed by trastuzumab were significantly higher than baseline values 3 months after the start of cancer treatment, and gradually decreased over the next 15 months (58, 59). This evidence concerns the gene MPO and cancer.